Complex assessment of bone mineral density, fracture risk, vitamin D status and bone metabolism in Hungarian systemic sclerosis patients by Horváth, Ágnes et al.
RESEARCH ARTICLE Open Access
Complex assessment of bone mineral
density, fracture risk, vitamin D status, and
bone metabolism in Hungarian systemic
sclerosis patients
Ágnes Horváth1, Edit Végh1, Anita Pusztai1, Zsófia Pethő1, Attila Hamar1, Monika Czókolyová1, Harjit Pal Bhattoa2,
Gábor Nagy2, Balázs Juhász3, Katalin Hodosi1, Andrea Domján1, Zoltán Szekanecz1,4*, Gabriella Szücs1
and Szilvia Szamosi1
Abstract
Objective: We wished to determine bone alterations in systemic sclerosis (SSc) patients by conventional
densitometry (DXA), peripheral quantitative computed tomography (pQCT), and bone biomarkers.
Methods: We included 44 SSc patients and 33 age-matched healthy controls. Lumbar spine and femoral neck
bone mineral density (BMD) was assessed by DXA. Volumetric BMD was measured by pQCT at the radius. FRAX, 25-
hydroxyvitamin-D3 (25-OH-D3), parathyroid hormone, osteocalcin, C-terminal collagen telopeptide, and procollagen
type I amino-terminal propeptide were also assessed.
Results: SSc patients had lower L2–4 BMD (0.880 ± 0.108 vs. 0.996 ± 0.181 g/cm2; p = 0.019) and femoral neck (FN)
BMD (0.786 ± 0.134 vs. 0.910 ± 0.090 g/cm2; p = 0.007) by DXA. In SSc vs. controls, pQCT indicated lower mean
cortical (328.03 ± 103.32 vs. 487.06 ± 42.45 mg/cm3; p < 0.001) and trabecular density (150.93 ± 61.91 vs. 184.76 ±
33.03 mg/cm3; p = 0.037). Vitamin D3 deficiency was more common in SSc vs. controls (60.0% vs. 39.3%; p = 0.003).
L2–4 (p = 0.002) and FN BMD (p = 0.015) positively correlated with BMI. pQCT assessments confirmed an inverse
correlation between pulmonary manifestation and total (p = 0.024), trabecular (p = 0.035), and cortical density (p =
0.015). Anti-Scl70 positivity inversely correlated with pQCT total density (p = 0.015) and the presence of digital ulcers
with cortical density (p = 0.001). We also found that vertebral and FN BMD as determined by DXA significantly
correlated with pQCT total, trabecular, and cortical density (p < 0.05).
Conclusion: The results of our study suggest that bone loss in SSc patients may be associated with lower BMI, anti-
Scl70 positivity, and the presence of pulmonary manifestations and digital ulcers. Both DXA and pQCT are
appropriate tools to evaluate the bone alterations in SSc patients.
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Key messages
 Bone loss in SSc patients may be associated with
lower BMI and anti-Scl70.
 Osteoporosis in SSc may be connected with
manifestations, such as pulmonary manifestations
and digital ulcers.
 Both DXA and pQCT may be suitable to assess
bone loss in SSc.
Introduction
Systemic sclerosis (SSc) is a chronic connective tissue
disease with a female predominance. There are three
main contributing factors in the pathogenesis of the dis-
ease: microvascular damage, activation of fibrosis in the
skin, as well as in the internal organs leading to exces-
sive collagen deposition, and pathological immune re-
sponses resulting in T-cell activation and autoantibody
production. Depending on the extent of skin involve-
ment and specific autoantibodies, two main subsets, the
limited cutaneous form (lcSSc) and the diffuse cutaneous
form (dcSSc), of the disease exist. The skin and internal
organ manifestations are well described and usually kept
in mind during regular follow-up over the disease
course. However, rather ignored musculoskeletal mani-
festations and osteoporosis (OP) may also have signifi-
cant impact on disability and quality of life of the
patients [1–3].
OP is associated with an increased risk of bone frac-
tures due to the microarchitectural deterioration of bone
tissue and a marked gradual loss of structural integrity.
It has been called as “silent epidemic” as it is a growing
problem and many patients are asymptomatic. There
have been great advances reached in risk stratification of
these patients in recent years [4]. Developing fracture
risk assessment tool (FRAX) by the World Health
Organization (WHO) task force in 2008 was a great leap
forward the so called personalized medicine, since it
provides a prediction tool for assessing an individual’s
risk of fracture in order to access path for treatment de-
cisions [5, 6]. The risk of OP is influenced by a number
of factors, including peak bone mass, race, older age,
family history of OP, decreased sex-hormone activity,
corticosteroid (CS) use, smoking, and excessive alcohol
use [4]. In addition, various chronic diseases that are ei-
ther associated with chronic inflammation or affect in-
testinal malabsorption or vitamin D metabolism may
also cause secondary bone loss [7–12]. The gold stand-
ard modality for measuring bone mineral density (BMD)
is dual-energy X-ray absorptiometry (DXA). The hip and
spine BMD T-scores derived from DXA became the
basis of the WHO criteria and it is used to define spe-
cific categories: normal, osteopenic, and osteoporotic pa-
tient groups [4, 5]. Although non-DXA technologies
cannot be used for conventional diagnostic classification,
peripheral quantitative computed tomography (pQCT) is
an established three-dimensional method to quantify
BMD in the spine, proximal femur, forearm, and tibia
which may predict fracture risk. The most important ad-
vantage of this technique is the unique ability to meas-
ure the cortical and trabecular bone separately [10, 13].
We have recently tested pQCT and compared this tech-
nique to DXA in rheumatoid arthritis (RA) patients [10].
Chronic autoimmune and inflammatory rheumatic
diseases are well-recognized risk factors for low BMD
resulting in a greater risk of fragility fractures. High
prevalence of vitamin D deficiency and low BMD has
been reported in patients with RA [7, 10, 11, 14], sys-
temic lupus erythematosus (SLE) [14–16], or undiffer-
entiated connective tissue disease (UCTD) [17]. Apart
from the traditional OP risk factors, systemic inflam-
mation plays a key role in accelerated inflammatory
bone loss [7, 18, 19]. Other factors, such as physical
inactivity and CS therapy, may also contribute to asso-
ciated OP in inflammatory rheumatic diseases [7, 19].
Patients with SSc are also at high risk of OP and fra-
gility fractures as a result of disease specific alterations
including immobilization due to flexion contractures
of the joints and muscle wasting, decreased vitamin D
synthesis in the fibrotic skin, gastrointestinal malab-
sorption, and renal insufficiency [8, 20–25]. Although
CS is not considered to have significant effect on bone
density in SSc patients because of its relatively short
term use, other medications, e.g., cyclophosphamide,
may cause early menopause which contributes indir-
ectly to OP in this group [8, 24]. Associations between
SSc subtype, extent of skin involvement, internal
organ affection, disease duration, autoantibody status,
and OP have been also hypothesized, but the real role
of these factors is still inconclusive [8, 24]. Further
studies with longer follow-up would be required to de-
termine whether these clinical parameters and
biochemical measures are real independent effect
modifiers in the development of OP in SSc patients.
Here, we investigated bone density in our SSc cohort
by conventional DXA and, for the first time, peripheral
QCT, in order to determine the 10-year risk of fracture
using FRAX tool and to study the relationship between
SSc-specific clinical and serological variables and low
BMD. We also evaluated vitamin D levels and bone bio-
markers and tried to find association of disease charac-
teristics and bone parameters.
Materials and methods
Patients and controls
We included selected 44 SSc patients (36 women, 8 men)
undergoing regular follow-ups at the outpatient clinic of
the Division of Rheumatology, University of Debrecen,
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between March 2016 and December 2017. We used a con-
venience sample and included patients that had been pre-
viously referred to DXA and QCT. They had a mean age
of 64.1 ± 9.0 years (range 41–82 years) and a mean disease
duration of 18.0 ± 5.9 years. We selected these patients
from the 252 SSc patients followed in our clinic (198
women and 54 men; mean age 61.2 ± 7.8 years; mean dis-
ease duration 16.8 ± 5.2 years). The study was approved by
the local ethics committee, and all patients signed a writ-
ten informed consent. All patients fulfilled the 2013 ACR/
EULAR classification criteria for SSc [26]. The control
group consisted of 33 age-matched healthy volunteers
from the hospital staff. Patients were classified as dcSSc
and lcSSc. Patients with diseases that may alter bone me-
tabolism, such as those with endocrine disorders, chronic
renal failure, liver disease, malignant hematopoietic dis-
eases, or bone tumors, were excluded. The study was ap-
proved by the Hungarian Scientific Research Council
Ethical Committee (approval No. 14804-2/2011/EKU).
Written informed consent was obtained from each pa-
tient, and assessments were carried out according to the
Declaration of Helsinki.
Clinical assessment
We recorded the following clinical parameters: age, dis-
ease duration, organ involvement, menopausal status,
and all relevant clinical risk factors (previous OP frac-
tures, parental hip fracture history, BMI, alcohol use,
smoking, and CS therapy) included in the FRAX by clin-
ical charts and also by using a questionnaire. Vascular
disease was defined by the presence of Raynaud’s syn-
drome and digital ulcers. With respect to digital ulcers,
we counted lesions that were greater than 3 mm in
diameter as a consequence of epithelium loss. Pulmon-
ary manifestations were diagnosed by chest X-ray and/or
high-resolution CT (HRCT) scan, and functional abnor-
malities were determined by pulmonary function test
(PFT) including diffusing capacity for carbon monoxide
(DLCO). Cardiac involvement was evaluated by echocar-
diography, while in cases of reasonable suspicion of pul-
monary arterial hypertension (PAH), right heart
catheterization (RHC) was performed. Gastrointestinal
manifestation was defined by the presence of dysphagia,
gastroesophageal reflux disease (GERD), and malabsorp-
tion syndrome. FRAX was assessed for all patients and
controls using the online FRAX tool provided by the
Centre for Metabolic Bone Diseases at Sheffield Univer-
sity (http://www.shef.ac.uk/FRAX/tool.jsp) [6] applying
the Hungarian population reference.
Immunolaboratory analyses and biomarkers of bone
metabolism
The following serological tests were performed to detect
autoantibodies: antinuclear antibodies (ANA) were
determined by indirect immunofluorescence on Hep2-
cells (Viro-Immun Labor-Diagnostika GmbH, Oberursel,
Germany). Anticentromere (ACA; Viro-Immun Labor-
Diagnostika GmbH) and anti-Scl70 antibodies (HYCOR
Biomedical, Garden Grove, CA, USA) were analyzed by
enzyme-linked immunosorbent assay (ELISA) in accord-
ance with the instructions of the manufacturers. Serum
levels of 25-hydroxy-vitamin D3 (25-OH-D3) were deter-
mined by high-pressure liquid chromatography (HPLC)
using the Jasco HPLC system (Jasco, Tokyo, Japan) and
Bio-Rad reagent kit (Bio-Rad Laboratories, Hercules,
CA, USA). According to the recommendation by
Dawson-Hughes et al. [27], patients with < 75 ng/ml 25-
OH-D3 levels had hypovitaminosis. Serum parathyroid
(PTH) hormone, osteocalcin (OC), C-terminal telopep-
tides of type I collagen (CTX), and procollagen type I
amino-terminal propeptide (P1NP) were also assessed
with a chemiluminescent enzyme-labeled immunometric
assay (Roche Diagnostics GmbH, Mannheim, Germany).
Bone mineral density measurements
In all SSc patients and healthy volunteers, BMD were
measured by DXA (Prodigy GE Lunar, GE-Lunar Corp.,
Madison, Wisc., USA) at the lumbar spine (L1–L4
BMD) and femoral neck (FN BMD). BMD values were
calculated in grams per square centimeter, and the re-
sults were expressed as T-score. Osteoporosis was de-
fined as a lumbar spine or FN BMD T-score ≤ 2.5 SD
according to the established WHO criteria. All BMD
measurements were carried out by the same two experi-
enced technicians.
At the time of DXA assessments, all patients and con-
trols were also evaluated for total, trabecular, and cor-
tical BMD of the dominant forearm by pQCT (Stratec
XCT-2000, Stratec Medizintechnik GmbH, Pforzheim,
Germany) as described before [10]. Data analysis was
performed using the XCT6.00B software (Stratec) with
measuring mask set to radius and threshold density to
269 mg/mm3 to define trabecular bone. BMD values are
expressed as milligrams per cubic centimeter.
Statistical analysis
Data analysis was performed using the SPSS Statistics
software, version 22.0 (IBM Corps, Armonk, NY, USA).
For descriptive statistics, data were presented as fre-
quency, range, median, and mean ± standard deviation
(SD). For comparisons between means, Student’s t test
was used. For comparison between qualitative variables,
independent t test and Mann-Whitney test were used.
Correlations were determined by calculating Pearson’s
correlation coefficient. Univariate and multiple regres-
sion analysis using the stepwise method was used to de-
termine correlations and independent associations
between parameters. DXA and pQCT parameters were
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the dependent variables and other parameters were inde-
pendent variables. The β standardized linear coefficients
showing linear correlations between two parameters
were determined. The B (+ 95% CI) regression coeffi-
cient indicated independent association between the
dependent and independent variable during changes. p
values < 0.05 indicated statistical significance.
Results
Clinical characteristics of SSc patients
The main demographic and disease-specific clinical
characteristics of SSc patients are summarized in Table 1.
Thirty-one patients (70.4%) were menopausal, and the
mean menopausal age was 46.1 ± 3.2 years. The mean
duration of menopause at the time of the study was
21.5 ± 7.8 years. Only one patient (2.2%) was a long-term
smoker and five patients (11.3%) reported habitual alco-
hol consumption. SSc patients had a mean BMI of
25.4 ± 3.9 kg/m2. Thirty-three patients (75%) had lcSSc,
and 11 patients (25%) had dcSSc. Regarding the cumula-
tive clinical features of SSc patients, interstitial lung dis-
ease (ILD) was most frequently seen (n = 35; 79.5%),
followed by cardiac involvement (n = 29; 65.9%), dyspha-
gia and GERD (n = 25; 56.8%), malabsorption syndrome
(n = 13; 29.5%), digital ulcers (n = 13; 29.5%), and PAH
(n = 3; 6.8%). None of the patients had notable renal in-
volvement. The prevalence of ANA positivity was 75%
(n = 33); ACA was present in seven cases (15.9%) and 11
patients (25%) were positive for anti Scl-70 antibodies.
Of the 44 SSc patients, 17 (38.6%) had ever been
treated with CS; however, we did not have an exact data
on the cumulative CS dose. Among the 17 patients, 13
(29.5%) received CS for less than 6 months. We did not
include those patients, who had been on long-term (≥ 1
year) CS therapy. Cyclophosphamide IV pulses were ad-
ministered to eight SSc patients with interstitial pneu-
monitis or with rapidly progressive skin symptoms at
doses of 750mg/m2 body surface area monthly for 6–12
months. Other immunosuppressive drugs, such as oral
methotrexate (MTX; 10–20 mg/week for a duration of
6–36 months) and azathioprine (AZA; 2 mg/kg) were
used in 13 patients (29.5%). One patient (2.2%) received
rituximab therapy for rapidly progressive skin disease
and severe arthritis.
With respect to the history of fractures, 19 patients
(43.2%) had altogether 23 vertebral and non-vertebral
osteoporotic fractures (hip, ankle, wrist), and occurrence
of hip fracture in the family history was determined in
four cases (9%).
Bone turnover metabolism and bone densitometry
assessments by DXA and QCT
Table 2 shows the bone turnover markers, the 10-year
probability of hip fracture, and major OP fractures
(spine, forearm, hip, or shoulder) as determined by
FRAX, the BMD values by DXA, prevalence of OP and
osteopenia according to the WHO classification, and
the pQCT measurements in patients with SSc and
healthy controls.
Table 1 Characteristics of SSc patients
Characteristics SSc (n = 44), mean
± SD or n (%)
Demographics and FRAX-related parameters
Age (years) 64.1 ± 9.0
BMI (kg/m2) 25.4 ± 3.9
Patients in menopause 31 (70.4)
Menopausal age (years) 46.1 ± 3.2
Duration of menopause (years) 21.5 ± 7.8
Current smoking 1 (2.2)
Alcohol intake 5 (11.3)
History of fracture 19 (43.2)
Family history of hip fracture 4 (9)
Disease characteristics
Disease duration (years) 18.0 ± 5.9
Type of disease
Limited cutaneous 33 (75)
Diffuse cutaneous 11 (25)
Current digital ulcers 13 (29.5)
Organ involvement
Interstitial lung disease 35 (79.5)
Cardiac involvement 29 (65.9)
Pulmonary arterial hypertension 3 (6.8)
Dysphagia and esophageal reflux disease 25 (56.8)
Malabsorption syndrome 13 (29.5)
Serological tests
Antinuclear antibody (ANA) positivity 33 (75)
Anticentromere antibody (ACA) positivity 7 (15.9)
Anti-topoisomerase I antibody (Scl-70) positivity 11 (25)
Treatment for SSc manifestations
Corticosteroid (short-term) 17 (38.6)
Cyclophosphamide 8 (18.1)
Other immunosuppressive drugs (MTX, AZA) 13 (29.5)
Rituximab 1 (2.2)
Treatment for OP
Calcium supplementation 32 (72.7)
Vitamin D supplementation 32 (72.7)
Bisphosphonates 16 (36.3)
Denosumab 2 (4.5)
Abbreviations: AZA azathioprine, BMI body mass index, FRAX fracture risk
assessment tool, MTX methotrexate. See text for further explanations
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Serum levels of calcium (2.41 ± 0.14 vs. 2.32 ± 0.11
mmol/l; p = 0.001) and PTH (5.47 ± 2.84 vs. 4.14 ± 1.38;
p = 0.008) were significantly higher in SSc patients than
in controls. Other bone markers, such as osteocalcin,
CTX, and P1NP, did not differ significantly between the
study groups. While the mean 25-OH-D3 levels were
also comparable in SSc and controls (53.96 ± 36.80 vs.
53.46 ± 16.35 nmol/L; p =NS), vitamin D deficiency (25-
OH-D3 levels < 50 nmol/L) in SSc patients (60%) was
significantly more common than in controls (39.3%; p =
0.003). Moreover, vitamin D insufficiency (25-OH-D3
levels < 75 nmol/L) was rather prevalent in both groups
(73% vs. 91%; p = 0.06) (Table 2).
The mean FRAX score for hip fractures was signifi-
cantly higher in SSc patients compared to controls
(4.00 ± 4.36 vs. 2.31 ± 2.49; p = 0.049). Similar differences
were found with respect to major fractures (13.48 ± 8.03
vs. 9.28 ± 5.13; p = 0.009) (Table 2).
Regarding DXA, SSc patients exerted significantly
lower L2–4 BMD (0.880 ± 0.108 vs. 0.996 ± 0.181 g/cm2;
p = 0.019), as well as FN BMD (0.786 ± 0.134 vs. 0.910 ±
0.090 g/cm2; p = 0.007), as determined by DXA. Further-
more, L2–4 (− 1.64 ± 1.48 vs. − 0.50 ± 0.92; p = 0.005)
and FN T-scores (− 1.78 ± 1.01 vs. − 0.44 ± 0.84; p <
0.001) were also significantly lower in SSc compared to
controls. According to the WHO classification (T-score
< 2.5), the prevalence of OP in SSc was 22.7% both at
the L1–4 and FN region. In contrast, none of the control
subject had OP at any measurement site.
Evaluation by pQCT indicated significantly lower
mean cortical bone density in SSc patients (328.03 ±
103.32 mg/cm3) compared to controls (487.06 ± 42.45
Table 2 Bone turnover markers and bone status evaluated with DXA and pQCT in SSc patients and controls
Parameter SSc (n = 44) Control (n = 33) p value
Bone turnover parameters
Total calcium (mmol/L; mean ± SD) 2.41 ± 0.14 2.32 ± 0.11 0.001
PTH (pmol/L; mean ± SD) 5.47 ± 2.84 4.14 ± 1.38 0.008
OC (μg/L; mean ± SD) 22.22 ± 9.54 25.2 ± 7.76 0.075
CTX-I (μg/L; mean ± SD) 0.359 ± 0.193 0.28 ± 0.2 0.051
P1NP (μg/L; mean ± SD) 49.38 ± 24.47 43.2 ± 21.9 0.135
25OH D (nmol/L; mean ± SD) 53.96 ± 36.80 53.46 ± 16.35 0.47
25OH levels < 75 nmol/L (n; %) 32 (73%) 30 (91%) 0.06
25OH levels < 50 nmol/L (n; %) 26 (60%) 13 (39.3%) 0.003
FRAX
Hip fracture (%; mean ± SD) 4.00 ± 4.36 2.31 ± 2.49 0.049
Major fracture (%; mean ± SD) 13.48 ± 8.03 9.28 ± 5.13 0.009
BMD
Lumbar spine (L2–4; g/cm2; mean ± SD) 0.880 ± 0.108 0.996 ± 0.181 0.019
Femoral neck (FN; g/cm2; mean ± SD) 0.786 ± 0.134 0.91 ± 0.09 0.007
T-score
Lumbar spine (L2–4; mean ± SD) − 1.64 ± 1.48 − 0.50 ± 0.92 0.005
Femoral neck (FN; mean ± SD) − 1.78 ± 1.01 − 0.44 ± 0.84 < 0.001
Femoral neck
Osteoporosis (n; %) 10 (22.7%) 0 (0%) 0.004
Osteopenia (n; %) 23 (52.2%) 15 (45.4%) 0.009
Lumbar spine
Osteoporosis (n; %) 10 (22.7%) 0 (0%) 0.004
Osteopenia (n; %) 16 (36.3%) 19 (57.5%) 0.106
Distal radius pQCT
Total density (mg/cm3; mean ± SD) 248.42 ± 70.94 347.94 ± 40.16 < 0.001
Cortical density (mg/cm3; mean ± SD) 328.03 ± 103.32 487.06 ± 42.45 < 0.001
Trabecular density (mgcm3; mean ± SD) 150.93 ± 61.91 184.76 ± 33.03 0.037
Abbreviations: BMD bone mineral density, CTX C-terminal telopeptides of type 1 collagen, D100 total volumetric BMD, Dcort volumetric cortical BMD, Dtrab
volumetric trabecular BMD, FRAX fracture risk assessment tool, OC osteocalcin, P1NP total procollagen type I amino-terminal propeptide, pQCT peripheral
quantitative computed tomography, PTH parathyroid hormone. See text for further explanations
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mg/cm3; p < 0.001) and lower mean trabecular density in
SSc (150.93 ± 61.91 mg/cm3) versus controls (184.76 ±
33.03 mg/cm3; p = 0.037). Similar observations were
made with regards to the total volumetric BMD at the
radius (D100) (248.42 ± 70.94 vs. 347.94 ± 40.16 mg/cm3;
p < 0.001) (Table 2).
Comparison of SSc subsets by qualitative variables
When assessing bone density and bone biomarkers in
different SSc subsets (Table 3), women had lower FN
BMD as determined by DXA, as well as lower total and
cortical density as measured by pQCT compared to men
(p < 0.05). SSc patients with pulmonary involvement
(ILD) had lower pQCT total, trabecular, and cortical
density vs. those without pulmonary involvement (p <
0.01). Patients with digital ulcer and those with anti-
Scl70 positivity exerted lower pQCT total and cortical
density in comparison to digital ulcer and anti-Scl70
negative patients (p < 0.05) (Table 3).
Multiple linear regression analysis was performed in
order to identify factors associated with low BMD
assessed by DXA and QCT in SSc patients (Table 4). In
our cohort, age inversely (p = 0.005; p = 0.027) and BMI
positively (p = 0.002; p = 0.015) correlated with L2–4 and
FN BMD, respectively, as determined by DXA. With re-
spect to the pQCT assessments, pulmonary manifesta-
tions inversely correlated with total (p = 0.024),
trabecular (p = 0.035), and cortical density (p = 0.015).
Moreover, anti-Scl70 positivity inversely correlated with
pQCT total density (p = 0.015) and the presence of
digital ulcers with cortical density (p = 0.001) (Table 4).
Among the 44 SSc patients, 19 had OP and 25 did not.
When comparing OP and non-OP patients, those with
OP were significantly older (69.4 ± 10.4 vs. 61.6 ± 10.1
years; p = 0.016), had lower BMI (23.0 ± 3.5 vs. 27.1 ± 5.0
kg/m2; p = 0.007), and had higher FN FRAX value
(6.07 ± 3.80 vs. 2.54 ± 4.20; p < 0.001) than those without
OP (data not shown).
Correlations between densitometry and pQCT bone
density values in SSc patients
Figure 1 presents the correlations between DXA and
pQCT parameters. The diagram shows that both verte-
bral and FN BMD as determined by DXA significantly
correlated with pQCT total, trabecular, and cortical
density (p < 0.05) (Fig. 2).
Discussion
OP has been associated with a number of inflammatory
rheumatic diseases including SSc [8, 12, 21, 25]. To our
knowledge, this may be the most complex study apply-
ing standard DXA, forearm pQCT, and FRAX, as well as
bone biomarkers in order to evaluate bone density and
bone turnover in SSc patients in comparison to healthy
controls. With respect to clinical features, 70% of SSc
patients were postmenopausal. In the past, more than
40% of the patients had fragility fractures. Menopause
plays an important role in the acceleration of bone loss.
Table 3 Comparison of SSc subsets by univariable analyses
Dependent variable Independent variable Univariable analysis
B (95% CI) β p value
DXA L2–4 BMD Age − 0.006 (− 0.010 to − 0.002) − 0.427 0.005
Age at dg. − 0.007 (− 0.013 to − 0.001) − 0.397 0.017
BMI 0.014 (0.005 to 0.022) 0.471 0.002
DXA FN BMD Age − 0.004 (− 0.007 to 0) − 0.324 0.027
BMI 0.009 (0.002 to 0.015) 0.346 0.027
Female vs. male − 0.131 (− 0.226 to − 0.036) − 0.392 0.008
pQCT total density Female vs. male − 69.529 (− 115.229 to − 23.826) − 0.382 0.004
Pulmonary manifestation − 51.367 (− 95.655 to − 7.078) − 0.423 0.024
Digital ulcer − 56.903 (− 97.273 to − 16.532) − 0.402 0.007
anti Scl70+ − 50.693 (− 91.123 to − 10.263) − 0.313 0.015
pQCT trabecular density Pulmonary manifestation − 48.234 (− 93.028 to − 3.440) − 0.318 0.035
ACA+ 91.292 (47.628 to 134.956) 0.546 0.001
pQCT cortical density Female vs. male − 120.46 (− 193.899 to − 47.021) − 0.455 0.002
Pulmonary manifestation − 82.502 (− 147.791 to − 17.212) − 0.326 0.015
Digital ulcer − 92.848 (− 146.016 to − 39.680) − 0.450 0.001
anti Scl70+ − 94.645 (− 161.926 to − 27.365) − 0.401 0.007
Abbreviations: ACA anti-centromere antibody, BMD bone mineral density, DXA dual-energy X-ray absorptiometry, FN femoral neck, pQCT peripheral quantitative
computed tomography. See text for further explanations
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Others reported significantly greater proportion of SSc
patients in menopause than in controls, which occurred
significantly earlier in that group [28]. Some authors also
noted a longer duration of menopause in SSc patients
[29]. In our study, the frequency of menopause was not
significantly different in SSc patients and age-matched
control group.
When the bone status of SSc patients was compared
to that of controls, vitamin D deficiency was more
prevalent in SSc versus controls. We [14, 22] and others
[30–33] have also found D hypovitaminosis in SSc.
Moreover, low vitamin D levels were associated with
organ manifestations, such as skin involvement [22].
It has been established that vitamin D is not only in-
volved in bone homeostasis, but also exerts import-
ant immunological effects [34, 35]. Thus, D
hypovitaminosis has been implicated in the patho-
genesis of various autoimmune diseases including
SSc [14, 16, 22, 33, 35, 36]. Impaired VDR signaling
in SSc has been reported, which, together with a de-
creased level of vitamin D, results in hypersensitivity
of SSc fibroblasts to TGF-β signaling, leading to an
uncontrolled activation of fibroblasts [31, 37]. Others
found that low levels of vitamin D were associated
with different disease activity markers in SSc (e.g.,
disease duration, ESR, CRP values, the presence of
ACA, systolic PAH, pulmonary fibrosis, and nailfold
capillaroscopic pattern) [30, 31, 38]. Our further
analyses revealed no significant associations between
low vitamin D level and any disease-specific mea-
sures, including disease subset, autoantibody positiv-
ity, or any organ manifestations.
Hip FRAX scores were also higher in SSc vs. controls.
Increased fracture risk associated with various risk fac-
tors has been reported in SSc [21]; however, we found
only one report on FRAX assessment in SSc. In that
study, the 10-year fracture risk was higher in SSc pa-
tients with low BMD [25].
Table 4 Multiple regression analysis of bone density and other parameters
Dependent variable Independent variable Multivariable analysis
B (95% CI) β p value
DXA L2–4 BMD Age − 0.006 (− 0.010 to − 0.002) − 0.427 0.005
BMI 0.014 (0.005–0.022) 0.471 0.002
DXA FN BMD Age − 0.004 (− 0.007 to 0) − 0.324 0.027
BMI 0.009 (0.002 to 0.015) 0.346 0.015
pQCT total density Pulmonary manifestation − 51.367 (− 95.655 to − 7.078) − 0.295 0.024
Scl70+ − 50.693 (− 91.123 to − 10.263) − 0.313 0.015
pQCT trabecular density Pulmonary manifestation − 48.234 (− 93.028 to − 3.440) − 0.318 0.035
pQCT cortical density Pulmonary manifestation − 82.502 (− 147.791 to − 17.212) − 0.326 0.015
Digital ulcer − 92.848 (− 146.016 to − 39.680) − 0.450 0.001
β standardized linear coefficient, B (+ 95% CI) regression coefficient, BMD bone mineral density, BMI body mass index, DXA dual-energy X-ray absorptiometry, FN
femoral neck, L lumbar, pQCT peripheral quantitative computed tomography. See text for further explanations
Fig. 1 Significant correlations between lumbar spine DXA and pQCT bone density values
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Regarding DXA, SSc patients had lower L2–4 and FN
BMD and T score values vs. controls. Moreover, WHO-
defined OP was more common is SSc. These data are in
line with previous reports. Studies in the literature sug-
gested that SSc is a risk factor for bone loss; however,
the prevalence of OP was within a wide range from 3 to
51%. This wide dispersion could be attributed to the het-
erogeneity of the patients studied (e.g., age, gender,
menopausal status, geographic location, disease subtype,
organ manifestations, and CS exposure) [8, 21, 23].
Other groups also reported lower BMD at multiple sites
in SSc [8, 23–25, 33].
In our cohort, total, trabecular, and cortical volumetric
BMD as determined by pQCT was lower in SSc com-
pared to controls. The difference was more pronounced
in cortical BMD. To our knowledge, there has been only
one study where bone pQCT was performed in SSc pa-
tients. In that study, Marot et al. [39] demonstrated sig-
nificant alterations in the trabecular bone compartment;
however, measures of the cortical compartment were
not different in SSc patients and controls.
In our study, we also compared DXA and pQCT. The
total, trabecular, and cortical density values determined
by QCT all significantly correlated with L2–4 and FN
BMD measured by DXA. We obtained similar results in
our recent study involving RA patients compared to
controls [10].
Among bone markers, we found elevated PTH levels
in SSc compared to controls. Others also reported
higher PTH in SSc [33]. In our cohort, OC, P1NP, and
CTX levels were similar in SSc and controls. With re-
spect to OC and P1NP, similar results were reported by
others [33, 40]. Allanore et al. [41] found elevated CTX
levels in 16 out of 33 patients. Moreover, we found
significant associations between gastrointestinal involve-
ment and levels of OC, P1NP, and CTX. Similar rela-
tionship has not yet been reported in SSc.
When assessing different SSc subsets, women had
lower DXA FN BMD than men. In addition, SSc patients
with pulmonary involvement, digital ulcers, and anti-
Scl70 positivity had greater bone loss as determined by
pQCT in comparison to patients without these features.
Moreover, dcSSc patients compared to lcSSc patients, as
well as patients with compared to without gastrointes-
tinal manifestations, exerted higher bone turnover as in-
dicated by bone biomarkers. In general, SSc patients
with OP were older, had lower BMI, and had higher hip
FRAX. Our study indicated significant, close correlations
between BMD determined by DXA and volumetric bone
density assessed by pQCT. Moreover, the multiple re-
gression analysis indicated that older age and lower BMI
were independently associated with lower L2–4 and FN
BMD by DXA. On the other hand, disease-specific mea-
sures, pulmonary manifestations, digital ulcers, and anti-
Scl70 positivity may determine pQCT volumetric density
values. Our data suggested BMI as an independent influ-
encing factor of FN and lumbar BMD by DXA. Others
reported reduced lean body mass in SSc patients due to
decreased physical activity, malnutrition, and CS treat-
ment, which may contribute to a reduced BMI. They
were also able to show that lower BMI was an independ-
ent risk factor for low BMD at the hip and femoral neck
[42]. With regard to bone biomarkers, Allanore et al.
[41] also found a correlation between CTX levels and
the presence of dcSSc vs. lcSSc, higher Rodnan skin
score, pulmonary manifestations, and anti-Scl70 positiv-
ity. In the abovementioned French study by Marot et al.
[39], the presence of ACA and digital ulcers were
Fig. 2 Significant correlations between femoral neck DXA and pQCT bone density values
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associated with low BMD by DXA at all sites and tra-
becular density by pQCT at tibia, highlighting the sus-
pected role of repeated vasospasm and subsequent
systemic microangiopathy in the alteration and resorp-
tion of bone tissue.
As mentioned above, pQCT studies performed in SSc
are scarce. In one study, the presence of digital ulcers
was associated with low BMD by DXA and highlighted
the suspected role of repeated vasospasm and subse-
quent systemic microangiopathy in the alteration and re-
sorption of bone tissue [39].
The strength of our study is the complexity of differ-
ent methods (DXA, pQCT, FRAX, bone markers) used
to assess bone status in SSc. There may be some limita-
tions, for example, the relatively small number of pa-
tients and controls included. In addition, some patients
received short-term CS treatment. Also, this was a
single-center study with a small number of patients, so it
may not be generalizable.
In conclusion, our study suggests that the existence of
OP, as well as BMD determined by traditional DXA,
shows association with general features, such as age or
BMI. On the other hand, volumetric bone density assessed
by pQCT, as well as bone biomarkers, rather showed asso-
ciations with SSc-specific features including dcSSc vs.
lcSSc subtype, organ manifestations (pulmonary, digital
ulcers, gastrointestinal), and anti-Scl70 positivity. These
data suggest that in dcSSc patients with extensive organ
involvement and anti-Scl70 positivity, pQCT and bone
biomarkers may have additional value during the assess-
ment of bone status. Larger cohort studies are needed in
order to determine the real place of these techniques in
determining bone status in SSc patients.
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